Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2009
01/22/2009US20090023742 Thiazolones for use as pi3 kinase inhibitors
01/22/2009US20090023741 Aryl/hetarylamides as modulators of the ep2 receptor
01/22/2009US20090023740 Sodium channel inhibitors
01/22/2009US20090023739 Capase inhibitors and uses thereof
01/22/2009US20090023738 Diaminopyrimidines as modulators of the ep2 receptor
01/22/2009US20090023737 Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands
01/22/2009US20090023736 Compounds for treating proliferative disorders
01/22/2009US20090023735 Sulphonamide Derivatives
01/22/2009US20090023734 Treating cell proliferative disorders
01/22/2009US20090023733 Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them
01/22/2009US20090023732 Citrate Salt of an Indole Derivative and its Pharmaceutical Use
01/22/2009US20090023731 Soluble epoxide hydrolase inhibitors
01/22/2009US20090023730 such as 1-(3-tert-butyl-1-methyl-1H-pyrazole-5-carbonyl)-3-(4-(pentyloxy)-3-(trifluoromethyl)phenyl)thiourea; packages, patches; hepatitis virus infections
01/22/2009US20090023729 Trisubstituted amine compound
01/22/2009US20090023728 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparations Thereof and Uses Thereof
01/22/2009US20090023727 Phthalazinone derivatives
01/22/2009US20090023726 ovarian cancer; HDAC inhibitors for example N-hydroxy-2-(4-(heteroarylmethylaminomethyl)piperidino)-pyrimidine-5-amide
01/22/2009US20090023725 Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors
01/22/2009US20090023724 Heteroaryl compounds, compositions thereof, and methods of treatment therewith
01/22/2009US20090023723 Purinone derivatives for treating neurodegenerative diseases
01/22/2009US20090023722 Amide substituted imidazoquinolines
01/22/2009US20090023721 Novel Substituted Tetracyclic Tetrahydrofuran, Pyrrolidine and Tetrahydrothiophene Derivatives and Their Use as a Medicament
01/22/2009US20090023720 2-Amino 1H-Imidazo Ring Systems and Methods
01/22/2009US20090023719 4-(Benzo[d]dioxol-4-ylamino)- or 4-(indazol-4-ylamino)- substituted 2,4-pyrimidinediamine derivatives: N4-(5-chlorobenzo[d][1,3]dioxol-4-yl)-N2-(2,6-dimorpholinopyridin-4-yl)pyrimidine-2,4-diamine; N-(4,6-dimorpholin-4-ylpyrimidin-2-yl)-N'-(1H-indazol-4-yl)-N'-methyl-pyrimidine-2,4-diamine; anticancer
01/22/2009US20090023718 Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives
01/22/2009US20090023717 Morphine-bridged indazole derivatives
01/22/2009US20090023716 Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents
01/22/2009US20090023715 Wound Healing
01/22/2009US20090023714 Combined preparation of a thiazide diuretic and a loop diuretic
01/22/2009US20090023713 Heterocyclic compounds
01/22/2009US20090023712 Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin
01/22/2009US20090023711 Piperazines and Piperidines as Mglur5 Potentiators
01/22/2009US20090023710 Compound
01/22/2009US20090023709 Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase
01/22/2009US20090023708 Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses
01/22/2009US20090023707 1-{4-[4-(pyrrolidin-1-ylmethyl)-1,3-oxazol-2-yl]benzyl}-1H-benzimidazole, used for the treatment of central nervous system disorders
01/22/2009US20090023706 Method of Treating Organophosphorous Poisoning
01/22/2009US20090023705 Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders
01/22/2009US20090023704 Novel Compounds 737
01/22/2009US20090023703 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
01/22/2009US20090023702 Pyridone gpr119 g protein-coupled receptor agonists
01/22/2009US20090023701 Cytokine Inhibitors
01/22/2009US20090023700 Neuroprotective treatments
01/22/2009US20090023699 Method For Obtaining a Natural Mixture of Conjugated Equine Estrogens Depleted in Non-Conjugated Lipophilic Compounds
01/22/2009US20090023698 Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid
01/22/2009US20090023697 Analgesia method
01/22/2009US20090023696 Use of c3-c10 17alfa-esters of 9,11-dehydrocortexolone as anti-gonadotrophic agents
01/22/2009US20090023695 METHOD OF MAKING AND USING 7alpha,11beta-DIMETHYL-17beta-HYDROXYESTR-4-EN-3-ONE 17-UNDECANOATE
01/22/2009US20090023694 Contraceptive
01/22/2009US20090023693 New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
01/22/2009US20090023692 Compositions for inhibiting and preventing vascular occlusion containing nutritional supplements
01/22/2009US20090023691 Delaying the ageing process and disorders caused by ageing
01/22/2009US20090023690 Oral drug delivery system
01/22/2009US20090023689 Oral drug delivery system
01/22/2009US20090023688 Microbicidal composition
01/22/2009US20090023686 combining citrate ion source, pyrophosphate ion source, and ferric ion source in water to form a solution, adding an organic solvent to precipitate solid ferric pyrophosphate citrate chelate composition, and isolating citrate chelate having 2% or less phosphate by weight; treating iron deficiency
01/22/2009US20090023685 Nebulized or Sprayed Cidofovir for Recurrent Respiratory Papillomatosis
01/22/2009US20090023684 Fluid for peritoneal dialysis
01/22/2009US20090023683 Complexes comprising zoledronic acid and cyclodextrins
01/22/2009US20090023682 Composition Comprising Dietary Fat Complexer and Methods of Using Same
01/22/2009US20090023681 Method of using beta-glucan from schizophyllum commune
01/22/2009US20090023680 treating advanced solid cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine
01/22/2009US20090023679 Compounds and methods for treatment of sickle cell disease or complications associated therewith
01/22/2009US20090023678 Amino Acid Vitamin Ester Compositions for Controlled Delivery of Pharmaceutically Active Compounds
01/22/2009US20090023677 via acyclic nucleoside analogs such as acyclovir and penciclovir; apoptosis
01/22/2009US20090023676 RNA Interference Mediated Inhibition of MAP Kinase Gene Expression or Expression of Genes Involved in MAP Kinase Pathway Using Short Interfering Nucleic Acid (SiNA)
01/22/2009US20090023675 RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA)
01/22/2009US20090023674 snRNA gene-like transcriptional units and uses thereof
01/22/2009US20090023673 Lipid containing formulations
01/22/2009US20090023672 Age-2 aptamer
01/22/2009US20090023671 Rnai Agents for Maintenance of Stem Cells
01/22/2009US20090023670 Regulation of Transgene Expression by RNA Interference
01/22/2009US20090023669 Antibacterial Agents
01/22/2009US20090023668 Method for treating blepharitis
01/22/2009US20090023666 Modulators of Hypoxia Inducible Factor-1 and Related Uses
01/22/2009US20090023665 Antibiotics ge 81112 factors a, b, b1, pharmaceutically acceptable salts and compositions, and use thereof
01/22/2009US20090023664 protease inhibitors such as 5-(dimethylamino)-N-[(2S,3R)-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl-(2-methylpropyl)amino]-1-phenylbutan-2-yl]-2-methylbenzamide, used for for treating human immunodeficiency virus (HIV) infections
01/22/2009US20090023659 Using cell surface adhesion proteins specific immunoglobulin to target therapeutics to tumorous; immunodiagnostics; immunotherapy
01/22/2009US20090023645 AIB1, a novel steroid receptor co-activator
01/22/2009US20090023639 Methods of Treatment
01/22/2009US20090023638 Spill resistant antibiotic formulations
01/22/2009US20090023628 Cosmetic Composition and a Process for Preparing This Cosmetic Composition and a Cosmetic Product
01/22/2009US20090023228 Dual-acting Imidazole antihypertensive agents
01/22/2009US20090023216 Double-Stranded Oligonucleotides
01/22/2009US20090023207 CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORS
01/22/2009US20090023152 Transcription factor MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances
01/22/2009US20090023147 Diagnostics and therapeutics for osteoporosis
01/22/2009US20090022831 Use of fructus schisandrae and extracts thereof in preventing and decreasing toxic and side effects of antineoplastic drugs
01/22/2009US20090022826 Multi-step method of pain and/or inflammation treatment
01/22/2009US20090022823 Methods for Administering Active Agents to CYP3A4 Sensitive Patients
01/22/2009US20090022821 Compositions from wax myrtle for the treatment of cancer, cardiovascular and inflammatory diseases
01/22/2009US20090022820 Compositions for sterilizing spores of spore -forming microorganisms comprising the extracts of torilidis fructus
01/22/2009US20090022818 High-foaming, viscous cleanser composition with a skin care agent
01/22/2009US20090022815 Halogenated composition, method for preparing same and uses thereof
01/22/2009US20090022814 Cancer treatment method
01/22/2009US20090022813 Composition for improving membrane composition and functioning of cells
01/22/2009US20090022808 Coated Hyaluronic Acid Particles
01/22/2009US20090022807 Drug formulations having inert sealed cores
01/22/2009US20090022806 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
01/22/2009US20090022804 Chemoembolisation